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Perioperative beta-blocker administration has recently been recommended for patients undergoing 
cardiac or other surgery due to the beneﬁcial cardiovascular eﬀects of these agents.  In addition,  some 
studies have reported that perioperatively administered beta-blockers also have analgesic eﬀects.  In 
this study,  to investigate the antinociceptive eﬀects and the analgesic proﬁle of landiolol,  we examined 
the eﬀects of intrathecal landiolol administration on nociceptive pain behavior and c-fos mRNA 
expression (a neural marker of pain) in the spinal cord using a rat formalin model.  We found that 
pain-related behavior was inhibited by intrathecal landiolol administration.  Moreover,  the increase in 
c-fos mRNA expression on the formalin-injected side was less pronounced in rats administered landi-
olol than in saline administered controls.  Thus,  intrathecal administration of landiolol exhibited anti-
nociceptive eﬀects.  Further investigation of the antinociceptive mechanism of landiolol is required.
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he 2006 American College of Cardiology/
American Heart Associationʼs guidelines for 
perioperative cardiovascular evaluation recommend the 
use of beta-blockers for patients undergoing vascular 
surgery and for high-risk patients undergoing non-
cardiac surgery [1].  In addition to their cardiovascu-
lar eﬀects,  these beta-blockers also have anesthetic 
eﬀects,  antinociceptive eﬀects,  and eﬀects on the 
central nervous system.  The antinociceptive eﬀects of 
beta-blockers have already been reported in clinical 
and experimental studies.  Clinical studies have 
reported that the perioperative use of beta-blockers 
results in analgesic eﬀects [2,  3].  Furthermore,  
basic studies using animal formalin models have indi-
cated that beta-blockers inhibit pain-related behaviors 
[4,  5].  However,  there has been no detailed biologi-
cal examination of the pain-relieving eﬀects of beta 
blockers,  and the mechanism by which they relieve 
pain remains unclear.
　 In this study,  we investigated the antinociceptive 
eﬀects of a short-acting beta-blocker,  landiolol,  using 
a rat formalin model.  We examined the eﬀects of 
intrathecal landiolol administration on nociceptive 
behaviors and on c-fos mRNA expression in the spinal 
cord.
Materials and Methods
　 Animal models. The Board of Animal Care 
and Use Committee of Okayama University approved 
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this study (OKU-2006103).  All eﬀorts were made to 
minimize animal suﬀering.
　 Male Sprague-Dawley rats (CLEA Japan,  Tokyo,  
Japan) weighing 300-350g were used.  The rats were 
housed individually in cages with a 12-h light/dark 
cycle.  Food and water were available ad libitum.
　 Rats were anesthetized by sodium pentobarbital 
(40mg/kg intraperitoneally).  Additional inhalation 
anesthesia with 1.5-2ｵ isoﬂurane in 100ｵ oxygen 
was given as needed.  An intrathecal catheter (SP-8;  
Natsume,  Tokyo,  Japan) was inserted between the L5 
and the L6 spinal vertebrae.  Landiolol (Ono 
Pharmaceutical Co.,  Ltd. ) (500µg,  Group L; n＝5) 
or the same volume of saline (Group C; n＝5) was 
administered into the subarachnoid space 1 week after 
intrathecal insertion of the catheter.
　 Immediately afterwards,  50µL of 5ｵ formalin was 
injected into the left plantar.  For behavioral assess-
ment,  we recorded the behavior of the animals using 
a digital camera and the ﬂinch counts were measured 
by playing back.  The numbers of ﬂinches were 
counted at 1 to 2min and at 6 to 7min after injection,  
and every 5min thereafter up to 50min after injection.  
The researcher who analyzed the behavior responses 
was blinded to the grouping.  The ﬂinch counts of the 
2 groups during phaseⅠ (0-10min after formalin injec-
tion) and phaseⅡ (20-50min after injection) were 
compared.  After observation of pain-related behavior 
for 50min,  the rats were sacriﬁced by decapitation 
under deep anesthesia with a pentobarbital overdose 
(60mg/kg).  The L4 and L5 spinal cord segments were 
rapidly dissected and divided into the left (ipsilateral) 
and right (contralateral) sides,  and these sides were 
collected.  Tissues were incubated in RNAlater (Qiagen,  
Germantown,  MD,  USA) and total RNA was extracted 
from each tissue using an RNeasy Lipid Tissue Mini 
Kit (Qiagen).  This RNA was used for quantiﬁcation 
of c-fos mRNA expression using the real-time 
RT-PCR method.
Quantitative real-time reverse transcription-
polymerase chain reaction (RT-PCR)
　 cDNA was reverse transcribed from 1µg of total 
RNA using a QuantiTect Reverse Transcription Kit 
(Qiagen).  cDNA solutions were diluted 10-fold with 
DNase-free water.  Templates were ampliﬁed in a 20-µL 
reaction mixture containing 10µL SYBR Premix Ex 
Taq (Takara-Bio,  Otsu,  Japan),  4.2µL DNase-free 
water,  0.2µM of forward and reverse primers and 
5µL diluted cDNA solution.  The primer sequences 
used are listed in Table 1.  Real-time PCR analysis 
was performed using a Light Cycler (Roche Diagnostics,  
Mannheim,  Germany) and the following ampliﬁcation 
conditions: 95℃ for 10 sec followed by 45 cycles of 
5 sec at 95-℃ and 20 sec at 60-℃.
　 To construct a plasmid standard,  each target was 
ampliﬁed by RT-PCR with the same primers as used 
for quantitative real-time PCR,  and the PCR product 
was sub-cloned into pCRII-TOPO (Invitrogen).  These 
plasmids were linearized by endonuclease digestion to 
avoid super-coiled structures.  The concentration of 
the plasmids was measured by spectrophotometry and 
this concentration was used to calculate absolute copy 
numbers of the plasmids.  Serial dilutions of each 
plasmid were ampliﬁed and quantiﬁed by real-time 
PCR to generate a standard curve.  The absolute copy 
number of c-fos cDNA in the samples was determined 
based on a corresponding standard curve.  Beta-Actin 
was used as an internal standard.  mRNA expression 
values are expressed relative to the expression on the 
contralateral side.  PCR speciﬁcity was conﬁrmed by 
sequencing,  gel electrophoresis,  and melting curve 
analysis.
　 Statistical analysis. All the data in this study 
are presented as means ± standard deviation (SD) and 
were analyzed using an unpaired t-test.  P＜0.05 was 
considered signiﬁcant.
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Table 1　 List of primers used for RT-PCR
Gene Primer Sequence (5ʼ-3ʼ) Amplicon size Accession No.
c-fos Forward: ggggacagcctttcctactaReverse: acggaggagaccagagtggg 185 bp NM_022197
beta-actin Forward: ctaaggccaaccgtgaaaagReverse: accctcatagatgggcacag 170 bp NM_031144
Results
　 Injection of 50µL of 5ｵ formalin into the left 
plantar of rat paws produced a typical biphasic pain 
behavior,  as assessed by the determination of ﬂinch 
counts,  in both the landiolol- and the saline-injected 
groups of rats.  The pain behavior of the 2 groups was 
then analyzed by comparing their ﬂinch counts.  The 
ﬂinch counts of the 2 groups were compared every 
5min and no signiﬁcant diﬀerences were observed for 
up to 30min.  From 35min onwards,  there was a sig-
niﬁcant diﬀerence between the 2 groups that persisted 
to the end of the observation period (Fig.  1).  Fig.  2 
shows the total number of ﬂinches in phase-Ⅰ (at 
1-2min and 5-6min after formalin injection) and 
phase-Ⅱ (at 21-22min and 31-32min,  and every 
5min up to 50min after formalin injection).  In the 
landiolol group (Group L),  both phase-Ⅰ and phase-Ⅱ 
pain-related behavior was inhibited compared with that 
in the control group (Group C) (total number of 
ﬂinches,  phase-Ⅰ,  Group C vs.  Group L: 38.4±14.5 
vs.  26.0±8.5,  p＜0.05; phase-Ⅱ,  Group C vs.  
Group L: 73.0±10.5 vs.  48.2±12.2,  p＜0.05).  In 
both groups,  c-fos mRNA expression,  as assessed by 
quantitative RT-PCR,  was higher on the formalin-
injected side than on the non-formalin-injected side.  
However,  this increase was less marked in Group L 
than in Group C (c-fos mRNA expression expressed as 
an ipsilateral: contralateral ratio,  Group C vs.  Group 
L: 1.84±0.16 vs. 1.26±0.17,  p＜0.01) (Fig.  3).
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Fig. 1　 Time course of the behavior of landiolol-treated rats in a 
rat pain model.  In the landiolol-treated group of rats,  pain-related 
behavior after formalin injection,  as assessed by the number of paw 
ﬂinches every 5min,  was decreased compared with that in the 
saline-treated group from 35min onwards.  ＊ﾝp＜0.05,  landiolol vs.  
saline group at the indicated time point (n＝5 per group).
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Fig. 2　 PhaseⅠ and Ⅱ behaviors -of landiolol-treated rats in a 
rat pain model.  In the landiolol-treated group of rats (Group L),  
both phase-Ⅰ and -Ⅱ pain-related behavior,  as assessed by the 
total number of paw ﬂinches in each phase,  was inhibited com-
pared with that of the saline-treated group (Group C).  Phase-
Ⅰ: Group C vs.  Group L: 38.4±14.5 vs.  26.0±8.5,  p＜0.05 (n
＝5 per group); phase-Ⅱ: Group C vs.  Group L: 73.0±10.5 vs.  
48.2±12.2,  p＜0.05 (n＝5 per group).
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Fig. 3　 c-fos mRNA expression in landiolol- and saline-treated 
rats following formalin injection.  In both rat groups,  c-fos mRNA 
expression,  as assessed by quantitative RT-PCR at 50min follow-
ing formalin injection and expressed as an ipsilateral (ipsi)/contral-
ateral (contra) ratio,  was higher on the formalin-injected side than 
on the non-formalin-injected side.  c-fos mRNA expression was 
decreased in the landiolol-treated group (Group L),  compared with 
that of the saline-treated group (Group C).  Group C vs.  Group 
L: 1.84±0.16 vs.  1.26±0.17,  p＜0.01 (n＝5).
Discussion
　 In this study,  intrathecal landiolol administration 
produced antinociceptive eﬀects in the rat formalin 
model.  We also conﬁrmed that c-fos mRNA expression 
in the spinal cord was decreased by administration of 
landiolol compared to the control.  This is the ﬁrst 
report in which antinociceptive eﬀects of the beta-
blocker landiolol were reported in rats,  not only based 
on behavior assessment but also based on the levels of 
an objective biological parameter.
　 The antinociceptive eﬀects of beta-blockers have 
been reported in previous clinical studies.  White et al.  
[2] reported that the postoperative opioid require-
ment was decreased by the use of esmolol during the 
intraoperative period.  Another report demonstrated 
that esmolol infusion during hysterectomy decreased 
patient-controlled intravenous morphine requirements 
in the postoperative period [3].  In experimental stud-
ies,  Davidson et al.  [4] reported that pain-related 
behaviors decreased with intravenous injection of 
esmolol in a rat formalin model; however,  they did not 
examine a pain-related biological parameter.  Zao et al.  
[5] reported that intrathecal landiolol administration 
had an antinociceptive eﬀect and decreased the 
expression of c-FOS protein in a mouse formalin 
model.  Although the antinociceptive eﬀects of beta-
blockers have been reported in both clinical and 
experimental studies,  the mechanisms that underlie 
these eﬀects remain unclear.
　 The formalin test is a widely used pain research 
model,  since the tissue injury and inﬂammation that 
result from formalin injection mimic human clinical 
pain conditions [6].  The formalin test results in 2 
phases of rat pain behavior.  Subcutaneous injection of 
diluted formalin into the rat hindpaw produces a 
biphasic pain behavioral response that consists of an 
early,  acute phase (phaseⅠ) and a late,  tonic phase 
(phaseⅡ).  The early phase starts immediately after 
formalin injection and lasts for about 10min.  The 
second phase starts 20min after formalin injection and 
lasts for 60min or longer.  During these 2 phases,  
pain behaviors such as ﬂinching (a brisk raising and 
shaking),  licking or biting of the aﬀected paw are 
observed,  and these behaviors are readily quantiﬁable.
　 In our study,  the frequency of ﬂinches that were 
measured over each 5-min interval after formalin 
injection was not signiﬁcantly diﬀerent between the 
landiolol- and saline-injected rats until 30min after 
formalin injection.  However,  from 35min onwards 
there was a signiﬁcant diﬀerence between the 2 
groups,  which persisted to the end of the experiment.  
The total number of ﬂinches of rats that were admin-
istered landiolol was inhibited in both phase-Ⅰ and 
phase-Ⅱ compared to the controls.  Regarding the pain 
mechanisms of the formalin test,  it is generally 
accepted that the pain in the ﬁrst phase is caused by 
direct peripheral nociceptive stimulation.  In contrast,  
the mechanism that induces pain in the second phase 
seems to be dependent on the combination of the inten-
sity of the nociceptive stimulus and on an inﬂamma-
tory reaction in the peripheral tissue [7].  The second 
phase is thought to reﬂect ongoing peripheral inﬂam-
matory input and the development of central sensitiza-
tion.  In previous studies,  it was reported that only 
high (150mg/kg/h) doses of esmolol infusion in rats 
decreased pain-related behaviors in phase-Ⅱ,  whereas 
low (40mg/kg/h) or high infusion doses did not aﬀect 
these behaviors in phase-Ⅰ [4].  It has also been 
demonstrated that,  during the formalin test,  only 
high-dose (750µg/kg) intrathecal administration of 
landiolol in mice decreases pain behaviors in both 
phase-Ⅰ and phase-Ⅱ,  while intrathecal administra-
tion of 250 and 500µg/kg landiolol displays antinoci-
ceptive eﬀects only in phase-Ⅱ [5].  These results,  
including the results of our study,  indicate that landi-
olol is more eﬀective in phase-Ⅱ than in phase-Ⅰ.  
This ﬁnding implies that landiolol provides analgesic 
eﬃcacy for inﬂammatory pain rather than for a nox-
ious stimulus.
　 We measured c-fos mRNA as a neural marker in 
addition to the pain behavior.  C-fos mRNA and its 
protein product Fos have been widely used as neural 
markers in pain research since their use by Hunt et al.  
[8].  C-fos is known as one of the immediate early 
genes (IEGs) which become activated within a short 
period of time after various stimuli,  including formalin 
injection,  and its expression does not require the 
synthesis of other proteins.  Fos,  produced by trans-
lating c-fos,  is a transcription factor which promotes 
the expression of a target gene by bining to an activa-
tor protein-1 site along with Jun.  Although IEG c-fos 
encodes for the nuclear protein Fos,  the decrease of 
c-fos mRNA by intrathecal landiolol injection in this 
study does not directly indicate pain relief.  We dem-
onstrated the change of neural activation by measuring 
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c-fos mRNA when the landiolol was injected intrathe-
cally in a rat formalin model.
　 Regarding potential mechanisms of the antinocicep-
tive eﬀects of beta-blockers,  it has been considered 
that beta-blockers might block tetrodotoxin-resistant 
Na channels [9] or contribute to antinociception via a 
central site [10].  Furthermore,  it has been reported 
that beta-blockers act on peripheral anti-inﬂammatory 
sites [11].  Further studies are required to elucidate 
the antinociceptive mechanisms of landiolol.
　 The dose of landiolol used in this study was deter-
mined based on the report of Zhao.  However,  in the 
end our dose was much higher because we could not 
observe suﬃcient analgesic eﬀects with the dose used 
by Zhao et al.  Their research was performed on mice,  
and we considered that the diﬀerence in species was 
probably responsible for the diﬀerence in eﬃcacy.  We 
cannot conjecture as to how these doses translate to 
clinical usage because,  to our knowledge,  there have 
been no reports on intrathecal landiolol administration 
in human.
　 In conclusion,  we have demonstrated that intrathe-
cal landiolol administration produced analgesic eﬀects 
in a rat formalin model.  We also showed that landiolol 
inhibits c-fos mRNA expression in the spinal cord.  
The analgesic eﬀects of landiolol might be exerted via 
an eﬀect on anti-inﬂammatory sites.
Acknowledgments.　There was no ﬁnancial support or sponsorship 
for this study.  None of the authors had any conﬂict of interest.
References
 1. Fleisher LA,  Beckman JA,  Brown KA,  Calkins H,  Chaikof E,  
Fleischmann KE,  Freeman WK,  Froehlich JB,  Kasper EK,  
Kersten JR,  Riegel B, Robb JF,  Smith SC Jr,  Jacobs AK,  Adams 
CD,  Anderson JL,  Antman EM,  Faxon DP,  Fuster V,  Halperin JL,  
Hiratzka LF,  Hunt SA,  Lytle BW,  Nishimura R,  Page RL and 
Riegel B: ACC/AHA 2006 guideline update on perioperative car-
diovascular evaluation for no cardiac surgery: focused update on 
perioperative beta-blocker therapy.  Circulation (2006) 113: 2662-
2674.
 2. White PF,  Wang B,  Tang J,  Wender RH,  Naruse R and Sloninsky 
A: The eﬀect of intraoperative use of esmolol and nicardipine on 
recovery after ambulatory surgery.  Anesth Analg (2003) 97: 1633-
1638.
 3. Chia YY,  Chan MH,  Ko NH and Liu K: Role of beta-blockade in 
anesthesia and postoperative pain management after hysterectomy.  
Br J Anaesth (2004) 93: 799-805.
 4. Davidson EM,  Doursout MF,  Szmuk P and Chelly JE:  
Antinociceptive and cardiovascular properties of esmolol following 
formalin injection in rats.  Can J Anaesth (2001) 48: 59-64.
 5. Zhao H,  Sugawara T,  Miura S,  Iijima T and Kashimoto S: Intrathecal 
lamdiolol inhibits nociception and spinal c-Fos expression in the 
mouse formalin test.  Can J Anaesth (2007) 54: 201-207.
 6. Tjolsen A,  Berge OG,  Hunskaar S,  Rosland JH and Hole K: The 
formalin test: an evaluation of the method.  Pain (1992) 51: 5-17.
 7. Yashpal K,  Mason P,  McKenna JE,  Sharma SK,  Henry JL and 
Coderre TJ: Comparison of the eﬀects of treatment with intrathe-
cal lidcaine given before and after formalin on both nociception 
and Fos expression in the spinal cord dorsal horn.  Anesthesiology 
(1998) 88: 157-164.
 8. Hunt SP,  Pini A and Evan G: Induction of c-fos-like protein in spi-
nal cord neurons following sensory stimulation.  Nature (1987) 328:  
632-634.
 9. Takahashi S,  Iida H,  Dohi S,  Oda A,  Osawa Y and Yamaguchi S:  
Comparative eﬀects of ultra-short-acting beta1-blockers on voltage-
gated tetrodotoxin-resistant Na+ channels in rat sensory neurons.  
Eur J Anaesthesiol (2009) 26: 196-200.
10. Radisavievic Z,  Cepeda C,  Peacock W,  Buchwald NA and Levine 
MS: Norepinephrine modulates excitatory amino acid-induced 
responses in developing human and adult rat cerebral cortex.  Int J 
Dev Neurosci (1994) 12: 353-361.
11. Kadoi Y and Saito S: Possible indications of beta-blockers in the 
perioperative period other than prevention of cardiac ischemia.  J 
Anesth (2010) 24: 81-95.
289Antinociceptive Eﬀects of LandiololApril 2012
